• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MaxCyte, Inc. - Common Stock (NQ:MXCT)

    0.7569 -0.0083 (-1.08%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 23, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 835,282
    Open 0.7700
    Bid (Size) 0.7303 (1,300)
    Ask (Size) 0.7830 (100)
    Prev. Close 0.7652
    Today's Range 0.7408 - 0.8000
    52wk Range 0.6434 - 3.170
    Shares Outstanding 105,482,558
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
    From MaxCyte, Inc
    Via GlobeNewswire

    Performance

    YTD
    -51.2%
    -51.2%
    1 Month
    +2.4%
    +2.4%
    3 Month
    -53.6%
    -53.6%
    6 Month
    -51.2%
    -51.2%
    1 Year
    -76.0%
    -76.0%

    More News

    Read More
    News headline image
    MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 12, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For November 5, 2025 ↗
    Via Benzinga
    News headline image
    MaxCyte Announces Planned CFO Transition in 2026
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    Insights into MaxCyte's Upcoming Earnings ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For August 6, 2025 ↗
    Via Benzinga
    News headline image
    MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗
    Via Benzinga
    News headline image
    Thursday's session: top gainers and losers ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    Which stocks are moving on Thursday? ↗
    Via Chartmill
    News headline image
    Traders are paying attention to the gapping stocks in Thursday's session. ↗
    Via Chartmill
    News headline image
    MaxCyte (MXCT) Q2 Revenue Drops 18% ↗
    Via The Motley Fool
    News headline image
    MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Signs Platform License Agreement with Adicet Bio
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
    From MaxCyte, Inc
    Via GlobeNewswire
    News headline image
    MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
    From MaxCyte, Inc
    Via GlobeNewswire

    Frequently Asked Questions

    Is MaxCyte, Inc. - Common Stock publicly traded?
    Yes, MaxCyte, Inc. - Common Stock is publicly traded.
    What exchange does MaxCyte, Inc. - Common Stock trade on?
    MaxCyte, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for MaxCyte, Inc. - Common Stock?
    The ticker symbol for MaxCyte, Inc. - Common Stock is MXCT on the Nasdaq Stock Market
    What is the current price of MaxCyte, Inc. - Common Stock?
    The current price of MaxCyte, Inc. - Common Stock is 0.7569
    When was MaxCyte, Inc. - Common Stock last traded?
    The last trade of MaxCyte, Inc. - Common Stock was at 03/23/26 04:00 PM ET
    What is the market capitalization of MaxCyte, Inc. - Common Stock?
    The market capitalization of MaxCyte, Inc. - Common Stock is 79.84M
    How many shares of MaxCyte, Inc. - Common Stock are outstanding?
    MaxCyte, Inc. - Common Stock has 80M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.